Conmed Forecasts Adjusted EPS for 2026 Amid Organic Growth Target
CONMED Corporation (NYSE: CNMD) reported Q2 2026 net sales of $343.5 million, with organic growth at 6% year-over-year and adjusted diluted earnings per share (EPS) reaching $1.38. The company attributed a portion of the EPS to an unexpected $0.21 benefit from tariff refunds. Looking ahead, Conmed forecasts its 2026 adjusted EPS will range between $4.48 and $4.60 while targeting organic growth in the 5% to 6% range for the year.
Tickers: $CNMD
Topics: earnings EPS performance sales growth